Literature DB >> 19357807

Ankylosing enthesitis associated with up-regulated IFN-gamma and IL-17 production in (BXSB x NZB) F(1) male mice: a new mouse model.

Yasuharu Abe1, Mareki Ohtsuji, Naomi Ohtsuji, Qingshun Lin, Hiromichi Tsurui, Susumu Nakae, Toshikazu Shirai, Katsuko Sudo, Sachiko Hirose.   

Abstract

We found that in contrast to (BXSB x NZB) F(1) female mice that spontaneously develop severe systemic lupus erythematosus (SLE), male (BXSB x NZB) F(1) mice are not prone to SLE, but instead develop seronegative ankylosing enthesitis in ankle/tarsal joints only when caged in groups, with the incidence reaching 83% at 7 months of age. This ankylosis is microscopically characterized by a marked proliferation of fibroblast-like cells positive for bone morphogenetic protein (BMP)-2 in association with heterotropic formation of cartilages and bones in hyperplastic entheseal tissues and subsequent fusion of tarsal bones. Elevated potentials of popliteal lymph node T cells producing interleukin (IL)-17 and interferon (IFN)-gamma were significantly associated with joint ankylosis, suggesting the involvement of these cytokines in effector phase mechanisms of the disease, including up-regulated BMP signaling pathways. There was no difference in serum autoantibody levels between affected and unaffected mice. Parental BXSB and NZB strains of both sexes did not develop the disease even when caged in groups, indicating that the disease develops under the control of susceptibility genes derived from both parental strains. These results indicate that (BXSB x NZB) F(1) male mice are a suitable model for clarifying genetic, environmental and molecular mechanisms underlying ankylosing enthesitis and related diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357807     DOI: 10.1007/s10165-009-0166-0

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  8 in total

1.  Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.

Authors:  Maria Sole Chimenti; Augusta Ortolan; Mariagrazia Lorenzin; Paola Triggianese; Marina Talamonti; Luisa Costa; Francesco Caso; Marta Favero; Miriam Teoli; Marco Galluzzo; Raffaele Scarpa; Leonardo Punzi; Roberto Perricone; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

Review 2.  Targeting the interleukin-23/17 axis in axial spondyloarthritis.

Authors:  Ananta Paine; Christopher T Ritchlin
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

3.  All-Trans Retinoic Acid Improves the Effects of Bone Marrow-Derived Mesenchymal Stem Cells on the Treatment of Ankylosing Spondylitis: An In Vitro Study.

Authors:  Deng Li; Peng Wang; Yuxi Li; Zhongyu Xie; Le Wang; Hongjun Su; Wen Deng; Yanfeng Wu; Huiyong Shen
Journal:  Stem Cells Int       Date:  2015-06-01       Impact factor: 5.443

4.  Increased CCL19 and CCL21 levels promote fibroblast ossification in ankylosing spondylitis hip ligament tissue.

Authors:  Yang Qin; Li Da He; Zhou Jian Sheng; Miao Ming Yong; Yang Sheng Sheng; Xu Wei Dong; Tong Wen Wen; Zou Yu Ming
Journal:  BMC Musculoskelet Disord       Date:  2014-09-26       Impact factor: 2.362

5.  IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis.

Authors:  Anita T Shaw; Yukiko Maeda; Ellen M Gravallese
Journal:  Arthritis Res Ther       Date:  2016-05-10       Impact factor: 5.156

6.  Anti-IL17A in Axial Spondyloarthritis-Where Are We At?

Authors:  Peter P Cheung
Journal:  Front Med (Lausanne)       Date:  2017-01-18

7.  Anti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcγRIIB-deficient mice.

Authors:  Mareki Ohtsuji; Qingshun Lin; Hideki Okazaki; Kazuko Takahashi; Hirofumi Amano; Hideo Yagita; Hiroyuki Nishimura; Sachiko Hirose
Journal:  Arthritis Res Ther       Date:  2018-02-08       Impact factor: 5.156

Review 8.  New developments in our understanding of ankylosing spondylitis pathogenesis.

Authors:  Aniruddha Voruganti; Paul Bowness
Journal:  Immunology       Date:  2020-08-17       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.